We describe a case of life-threatening disseminated coccidioidomycosis in a previously healthy child. Like most patients with disseminated coccidioidomycosis, this child had no genomic evidence of any ...

Interferons (IFs) and interleukins (ILs) are immune system biochemicals at the intersection of basic research and medical technology. Part of the class of secreted cellular regulators known as ...

Hydrocephalus following IVH represents a major complication of preterm birth and may result in adverse neurologic outcome in later life. IVH is associated with damage to the white matter, which is ...

In a recent study posted to the medRxiv* preprint server, researchers compared serum cytokine expression among healthy individuals and those with PASC [post-acute sequelae of coronavirus disease 2019 ...

A randomized prospective study of low-dose interleukin-2 (IL-2) in combination with interferon-alpha (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma: Final results No significant ...

Treatment of Relapsed Wilms’ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children’s Memorial Hospital Interleukin-12 (IL-12) and interferon alfa-2b ...

"We found that serum concentrations of IL-17F alone did not predict response to interferon beta-1b therapy in patients with relapsing-remitting multiple sclerosis." The study concludes, "Given the ...

Cytokines, unique growth factors that are secreted by various cells of the body, include interleukins (ILs), interferons (IFNs), and tumor necrosis factors (TNFs). These proteins bind to target cell ...

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented ...

BALTIMORE – March 11, 2003 – Proteins produced by the immune system, known as interferons, may be an effective treatment for smallpox, say researchers today at the American Society for Microbiology’s ...

With its sights set on a series A and an IPO following a £3.5 million (US$4.4 million) investment round in 2021, Scottish biotech ILC Therapeutics Ltd. is hoping to make waves with a sublingual ...